

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Exidot 400 mg Spot-on solution for Extra Large Dogs (FR, IE, IT)

Duo- Op 400 mg Spot-on solution for Extra Large Dogs (NL)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 4.0 ml pipette contains:

Active substance:

Imidacloprid 400 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Butylhydroxytoluene (E 321)	4.0 mg
Benzyl alcohol (E 1519)	
Propylene carbonate	

3. CLINICAL INFORMATION

3.1 Target species

Dogs.

3.2 Indications for use for each target species

For the prevention and treatment of flea infestations and for the treatment of biting lice (*Trichodectes canis*) on dogs weighing 25 kg and greater.

Fleas on dogs are killed within one day following treatment. One treatment prevents further flea infestation for four weeks.

The veterinary medicinal product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD) where this has been previously diagnosed by a veterinary surgeon.

3.3 Contraindications

Do not treat unweaned puppies of less than 8 weeks of age.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

Re-infestation from emergence of new fleas in the environment may continue to occur for six weeks or longer after treatment is initiated. More than one treatment may therefore be required, depending on the level of fleas in the environment. To aid reduction in environmental challenge, the additional use of a suitable environmental treatment against adult fleas and their developing stages is recommended. In order to reduce further the environmental challenge, it is recommended that all cats, rabbits and dogs in

the household are treated. Treatment of nursing bitches controls flea infestations on both dam and offspring.

The veterinary medicinal product remains effective if the animal becomes wet, for example after exposure to heavy rain. However, re-treatment may become necessary, depending on the presence of fleas in the environment. In these cases do not treat more frequently than once weekly.

In case of biting lice infestation in dogs, a veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

Use the appropriate product for Dogs based on bodyweight.

3.5 Special precautions for use

Special precautions for safe use in the target species:

For external use only.

Apply only to undamaged skin.

Care should be taken to avoid the contents of the pipette coming into contact with the eyes or mouth of the recipient animal. Do not allow recently treated animals to groom each other.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product contains benzyl alcohol and may cause skin sensitisation or transient skin reactions in rare cases (for example, irritation, tingling) and/or eye irritation.

Avoid contact between the veterinary medicinal product and skin, eyes or mouth.

People with known hypersensitivity to the active ingredient or any of the excipients should avoid contact with the veterinary medicinal product.

Do not eat, drink or smoke during application.

Do not massage the application site. After application, do not stroke or groom animals until application site is dry.

Wash off any skin contamination with soap and water. Wash hands thoroughly after use.

If the veterinary medicinal product gets into eyes accidentally, the eyes should be thoroughly flushed with water.

If skin or eye irritation persists, obtain medical attention.

If the veterinary medicinal product is accidentally swallowed, obtain medical attention immediately.

Special precautions for the protection of the environment:

Imidacloprid is toxic to aquatic organisms. Treated dogs should not be allowed to enter surface water for 48 hours after treatment, to avoid adverse effects on aquatic organisms.

Other precautions:

The solvent in this veterinary medicinal product may stain certain materials including leather, fabrics, plastics and finished surfaces. Allow the application site to dry before permitting contact with such materials.

3.6 Adverse events

Dogs:

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Agitation Hypersalivation ¹ Neurological signs (e.g. Depression, Incoordination, Tremor) Application site reaction (e.g. Hair loss, Itching, Reddening of the skin, Skin lesion)
--	--

¹ May occur if the dog licks the application site immediately after treatment due to the bitter taste. This is not a sign of intoxication and disappears within some minutes without treatment.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Laboratory studies in rats and rabbits have not produced any evidence of embryotoxic, teratogenic or reproductive toxic effects. Studies on pregnant and lactating bitches together with their offspring are limited.

Evidence so far suggests that no adverse effects are to be expected in these animals.

3.8 Interaction with other medicinal products and other forms of interaction

No incompatibility has been observed between this product at twice the recommended dose and the following commonly used veterinary products: lufenuron, pyrantel and praziquantel and febantel. The compatibility of the veterinary medicinal product was also demonstrated with a wide range of routine treatments under field conditions including vaccination.

3.9 Administration routes and dosage

Spot-on use.

Animals should be weighed accurately prior to treatment.

Dosage and Treatment Schedule

Dog (kg bw)	Number of Pipettes	Imidacloprid (mg/kg bw)
≥ 25 to < 40 kg	1 x 4.0 ml	minimum of 10
≥ 40 kg	2 x 4.0 ml	minimum of 10

Method of administration:

Hold the pipette upright. Tap the narrow part of the pipette to ensure the contents remain within the main body of the pipette. Snap back the tip. Part the coat on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the pipette on the skin and squeeze the pipette several times to empty its contents completely and directly onto the skin in one spot.

Temporary changes to the coat (clumped/greasy hair) may be noted at the application site.

For dogs of 25 kg body weight and greater:

The dog should be standing for easy application. The entire contents of the pipette(s) should be applied evenly to three or four spots all located at different application sites along the dog's backline from the shoulder to the base of the tail. At each spot part the coat until the skin is visible. Place the tip of the pipette on the skin and gently squeeze to expel a portion of the contents directly onto the skin.

Do not apply an excessive amount of solution at any one spot that could cause some of the solution to run off the side of the dog.

Correct application will minimise the opportunity for the dog to lick the veterinary medicinal product.

Apply only to undamaged skin.

Do not allow recently treated animals to groom each other.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No adverse clinical signs were produced by either individual doses of up to 200 mg/kg body weight (five to eight times the therapeutic dose), daily treatments at 100 mg/kg body weight for five consecutive days or weekly treatments at five times the maximum dose rate for eight consecutive weeks.

In rare cases of overdose or licking of treated fur, nervous system disorders (such as twitching, tremors, ataxia, mydriasis, miosis, lethargy) can occur.

Poisoning following inadvertent oral uptake in animals is unlikely. In this event, treatment should be symptomatic under veterinary medical attention. There is no known specific antidote but administration of activated charcoal may be beneficial.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QP53AX17

4.2 Pharmacodynamics

Imidacloprid, 1-(6-Chloro-3-pyridylmethyl)-N-nitro-imidazolidin-2-ylideneamine is an ecto-parasiticide belonging to a group of chloronicotinyl compounds. Chemically, it is more accurately described as a chloronicotinyl nitroguanidine.

The substance has a high affinity for the nicotinic acetylcholine receptors in the post-synaptic region of the central nervous system (CNS). The ensuing inhibition of cholinergic transmission in insects results in paralysis and death. Due to the weak nature of the interaction with mammalian nicotinic receptor sites and the postulated poor penetration through the blood/brain barrier in mammals, it has virtually no effect on the mammalian CNS. The minimal pharmacological activity in mammals is supported by safety studies involving systemic administration of sub-lethal doses to rabbits, mice and rats.

In further studies, in addition to the adulticide flea efficacy of imidacloprid, a larvicidal flea activity in the surroundings of the treated pet has been demonstrated. Larval stages in the pet's surroundings are killed following contact with a treated animal.

4.3 Pharmacokinetics

Following topical application in dogs, the solution is quickly distributed over the animal. Target animal overdose and serum kinetic studies have established that systemic absorption is very low, transient and not relevant for the clinical efficacy. This has been further demonstrated by a study in which fleas were not killed after having fed on previously treated animals once the animal's skin and fur had been cleaned of all active material.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

None known.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

5.3 Special precautions for storage

Store in the original package in order to protect from light.

This veterinary medicinal product does not require any special temperature storage conditions.

5.4 Nature and composition of immediate packaging

A white pipette composed of a heat-formed shell of a polypropylene/cyclic olefin copolymer/polypropylene layer and a polyethylene/ethylene vinyl alcohol/polyethylene layer.

Cardboard Box with 1, 2, 3, 4, 6, 8, 9, 10, 12, 15, 18, 20, 21, 24, 30, 60, 90, 150 or 160 pipettes in individual foil sachets.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

The veterinary medicinal product should not enter water courses as imidacloprid may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd

7. MARKETING AUTHORISATION NUMBER(S)

8. DATE OF FIRST AUTHORISATION

<Date of first authorisation:> <{DD/MM/YYYY}> <{DD month YYYY}.>

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

<{MM/YYYY}>

<{DD/MM/YYYY}>

<{DD month YYYY}>

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

IE: Veterinary medicinal product subject to prescription.

FR, IT, NL: Veterinary medicinal product not subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

{Carton}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Exidot 400 mg Spot-on solution for Extra Large Dogs weighing 25 kg and greater (FR, IE, IT)

Duo- Op 400 mg Spot-on solution for Extra Large Dogs weighing 25 kg and greater (NL)

2. STATEMENT OF ACTIVE SUBSTANCES

Imidacloprid 400 mg/pipette

3. PACKAGE SIZE

1 x 4.0 ml
2 x 4.0 ml
3 x 4.0 ml
4 x 4.0 ml
6 x 4.0 ml
8 x 4.0 ml
9 x /4.0 ml
10 x 4.0 ml
12 x 4.0 ml
15 x 4.0 ml
18 x 4.0 ml
20 x 4.0 ml
21 x 4.0 ml
24 x 4.0 ml
30 x 4.0 ml
60 x 4.0 ml
90 x 4.0 ml
150 x 4.0 ml
160 x 4.0 ml

4. TARGET SPECIES

Dogs

5. INDICATIONS*For products not subject to veterinary prescription*Dogs:

For the prevention and treatment of flea infestations and for the treatment of biting lice (*Trichodectes canis*) on dogs.

Use the appropriate product for Dogs based on bodyweight.

Fleas on dogs are killed within one day following treatment. One treatment prevents further flea infestation for four weeks.

The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD) where this has been previously diagnosed by a veterinary surgeon.

6. ROUTES OF ADMINISTRATION

Spot-on use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Store in the original package in order to protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”
--

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”
--

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
--

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd

14. MARKETING AUTHORISATION NUMBERS
--

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

{Sachet}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
--

Exidot 400 mg Spot-on solution for Extra Large Dogs weighing 25 kg and greater (FR, IE, IT) 

Duo- Op 400 mg Spot-on solution for Extra Large Dogs weighing 25 kg and greater (NL) 

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Imidacloprid 400 mg/pipette

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

{Pipette}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Exidot 400 mg Spot-on  (FR, IE, IT)

Duo- Op 400 mg Spot-on  (NL)

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

4.0 ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}